List of publications

All the publications of the C3M teams.

Export in CSV
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.

Authors Luci C, Vieira E, Bourinet M, Rousseau D, Bonnafous S, Patouraux S, Lefevre L, Larbret F, Prod'homme V, Iannelli A, Tran A, Anty R, Bailly-Maitre B, Deckert M, Gual P

Cellular and molecular gastroenterology and hepatology Jan 2022

Deubiquitinase Inhibitors Impair Leukemic Cell Migration Through Cofilin Oxidation and Alteration of Actin Reorganization.

Authors Larbret F, Biber P, Dubois N, Ivanov S, Lafanechere L, Tartare-Deckert S, Deckert M

Frontiers in pharmacology Jan 2022

Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.

Authors Buffard M, Naldi A, Freiss G, Deckert M, Radulescu O, Coopman PJ, Larive RM

Biomolecules Feb 2021

A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.

Authors Alcaraz LB, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Du Manoir S, Huesgen PF, Overall CM, Tartare-Deckert S, Jacot W, Chardès T, Guiu S, Roger P, Reinheckel T, Moali C, Liaudet-Coopman E

Theranostics Jan 2021

Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment.

Authors Lebrun-Frenay C, Berestjuk I, Cohen M, Tartare-Deckert S

Neurology and therapy Dec 2020

[Melanoma therapeutic escape: the biomechanical track].

Authors Lecacheur M, Girard CA, Deckert M, Tartare-Deckert S

Medecine sciences : M/S Nov 2020

Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8 T-cell evasion.

Authors Elasifer H, Wang ECY, Prod'homme V, Davies J, Forbes S, Stanton RJ, Patel M, Fielding CA, Roberts D, Traherne JA, Gruber N, Bugert JJ, Aicheler RJ, Wilkinson GWG

The Journal of general virology Aug 2020

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf Melanoma.

Authors Signetti L, Elizarov N, Simsir M, Paquet A, Douguet D, Labbal F, Debayle D, Di Giorgio A, Biou V, Girard C, Duca M, Bretillon L, Bertolotto C, Verrier B, Azoulay S, Mus-Veteau I

Cancers Jun 2020

A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.

Authors Girard CA, Lecacheur M, Ben Jouira R, Berestjuk I, Diazzi S, Prod'homme V, Mallavialle A, Larbret F, Gesson M, Schaub S, Pisano S, Audebert S, Mari B, Gaggioli C, Leucci E, Marine JC, Deckert M, Tartare-Deckert S

Cancer research May 2020

Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.

Authors Diazzi S, Tartare-Deckert S, Deckert M

Cancers May 2020